Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Moodys
Citi
McKinsey
Fuji

Generated: September 16, 2019

DrugPatentWatch Database Preview

Patent: 7,998,481

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,998,481
Title:Modulation of NKG2D for treating or preventing solid organ allograft rejection
Abstract: The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.
Inventor(s): Kang; Sang-Mo (San Francisco, CA), Lanier; Lewis L. (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:11/429,354
Patent Claims:see list of patent claims

Details for Patent 7,998,481

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Try a Free Trial The Regents of the University of California (Oakland, CA) 2024-04-05 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12   Try a Free Trial The Regents of the University of California (Oakland, CA) 2024-04-05 RX search
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 001 2016-05-27   Try a Free Trial The Regents of the University of California (Oakland, CA) 2024-04-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
US Department of Justice
Julphar
Baxter
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.